Abstract
Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development. © 2007 Nature Publishing Group.
Cite
CITATION STYLE
APA
Trull, M. C., Du Laney, T. V., & Dibner, M. D. (2007, February). Turning biodefense dollars into products. Nature Biotechnology. https://doi.org/10.1038/nbt0207-179
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free